Selected article for: "necrosis factor and study aim"

Author: Megna, Matteo; Ocampo-Garza, Sonia Sofia; Potestio, Luca; Fontanella, Giuseppina; Gallo, Lucia; Cacciapuoti, Sara; Ruggiero, Angelo; Fabbrocini, Gabriella
Title: New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
  • Cord-id: 5n3xsxs5
  • Document date: 2021_10_15
  • ID: 5n3xsxs5
    Snippet: Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biolo
    Document: Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature. For each patient, age, sex, psoriasis duration, psoriasis severity, comorbidities, and previous and current psoriasis treatments were collected, and each subject was screened for PsA using the Early ARthritis for Psoriatic patient (EARP) questionnaire every 3 months for 1 year. New-onset PsA was diagnosed in 10 (8.5%) out of 118 patients (three male, 30.0%; mean age 44.5 years) involving every different biologic class (anti-TNF, anti-IL12/23, anti-IL17, and anti-IL23). No significant risk factor for new-onset PsA was identified; no significant difference was found comparing patients who developed PsA and subjects who did not develop PsA regarding psoriasis severity, past/current therapies, and comorbidities. Clinicians must keep in mind the possibility of PsA onset also in patients undergoing biologics so that PsA screening should be strongly recommended at each follow-up.

    Search related documents:
    Co phrase search for related documents
    • activity severity and low disease activity: 1, 2, 3
    • activity severity and magnetic resonance: 1, 2
    • activity severity and magnetic resonance imaging: 1, 2
    • low disease activity and magnetic resonance: 1, 2
    • low disease activity and magnetic resonance imaging: 1, 2
    • low disease and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • low disease and magnetic resonance imaging: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • low efficacy and magnetic resonance: 1, 2, 3
    • low efficacy and magnetic resonance imaging: 1, 2
    • low number and magnetic resonance: 1, 2, 3
    • low number and magnetic resonance imaging: 1, 2, 3
    • low percentage and magnetic resonance: 1, 2
    • low percentage and magnetic resonance imaging: 1, 2